摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[2-(2-丙氧基乙氧基)乙氧基]乙醇 | 23305-64-8

中文名称
2-[2-(2-丙氧基乙氧基)乙氧基]乙醇
中文别名
——
英文名称
2-[2-(2 propoxyethoxy)ethoxy]-ethanol
英文别名
triethylene glycol monopropyl ether;triethylene glycol propyl ether;tri(ethylene glycol) propyl ether;2-[2-(2-propoxy-ethoxy)-ethoxy]-ethanol;triethyleneglycol monopropyl ether;2-(2-(2-Propoxyethoxy)ethoxy)ethanol;2-[2-(2-propoxyethoxy)ethoxy]ethanol
2-[2-(2-丙氧基乙氧基)乙氧基]乙醇化学式
CAS
23305-64-8
化学式
C9H20O4
mdl
MFCD06252454
分子量
192.255
InChiKey
KCBPVRDDYVJQHA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    138 °C(Press: 10 Torr)
  • 密度:
    0.9990 g/cm3
  • 物理描述:
    Liquid

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    13
  • 可旋转键数:
    10
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    47.9
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2909499000

SDS

SDS:d0cd9d85a8067c0df39455bda10d5663
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[2-(2-丙氧基乙氧基)乙氧基]乙醇吡啶氯化亚砜 、 sodium hydroxide 作用下, 以 甲苯 为溶剂, 反应 21.0h, 生成 N-(2-hydroxyethyl)-N,N-dimethyl-N-{2-[2-(2-propyloxyethoxy)ethoxy]ethyl}ammonium chloride
    参考文献:
    名称:
    在氮原子上含有ω-烷氧基乙基和2-羟乙基取代基的无环季铵化合物的合成
    摘要:
    一系列无环对称季铵氯化物 Me2(HOCH2CH2)N+(CH2CH2O)nR Cl– (n = 1, R = n-C9H19; n = 2, R = n-C6H13; n = 3, R = n-C3H7)由相应的叔胺 Me2N(CH2CH2O)nR 与亚乙基氯醇在两相系统中烷基化合成,使用水作为溶剂。叔胺是在非均相系统有机相 - 水相中合成的,使用 Me2NH 和固体碱的水溶液。通过在二恶烷中使用固体 KOH 进行相转移烷基化,以高收率获得了乙烯、二甘醇和三甘醇的中间体单醚。合成的胺和氯化铵的 NMR 光谱中的质子和碳原子信号是基于异核相关性 (1H, 13C) 的数据分配的。
    DOI:
    10.1007/s11172-015-1209-7
  • 作为产物:
    描述:
    溴丙烷 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 反应 1.5h, 以18%的产率得到2-[2-(2-丙氧基乙氧基)乙氧基]乙醇
    参考文献:
    名称:
    Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
    摘要:
    脂肪酸组成物用于制备药物,例如蛋白质和肽,蛋白质和肽共轭物以及/或阳离子-多肽共轭物复合物的给药。特别地,本发明提供了一种固体制剂,用于经口摄入口服,其含有约0.1至约75%w/w的脂肪酸成分,其中所述脂肪酸成分包括饱和或不饱和的C4,C5,C6,C7,C8,C9,C10,C11或C12脂肪酸和/或这些脂肪酸的盐;以及治疗剂。此外,本发明提供了一种液体制剂,用于经口摄入口服,包括:约0.1至约10%w/v的脂肪酸成分,其中所述脂肪酸成分包括饱和或不饱和的C4,C5,C6,C7,C8,C9,C10,C11或C12脂肪酸和/或这些脂肪酸的盐;以及治疗剂。
    公开号:
    US20060018874A1
点击查看最新优质反应信息

文献信息

  • [EN] POLYMERS PREPARED FROM MIXTURES OF MULTIFUNCTIONAL N-VINYLFORMAMIDE AND HYBRID REACTIVE N-VINYLFORMAMIDE CROSSLINKING MONOMER MOIETIES AND USES THEREOF<br/>[FR] POLYMÈRES PRÉPARÉS À PARTIR DE MÉLANGES DE FRAGMENTS MONOMÈRES DE RÉTICULATION N-VINYLFORMAMIDE MULTIFONCTIONNELS ET N-VINYLFORMAMIDE RÉACTIFS HYBRIDES ET LEURS UTILISATIONS
    申请人:ISP INVESTMENTS INC
    公开号:WO2011084993A1
    公开(公告)日:2011-07-14
    The present invention provides polymers resulting from polymerization of at least one reactive vinyl monomer moiety and a multifunctional N-vinylformamide crosslinking moiety; polymers resulting from polymerization of at least one reactive vinyl monomer moiety and a hybrid N-vinylformamide crosslinking moiety having at least one N-vinylformamide functionality and at least one other reactive vinyl functionality; polymers resulting from polymerization of at least one hybrid reactive N-vinylformamide monomer moiety having one N-vinylformamide functionality and at least one other reactive non-vinyl functionality and a multifunctional N-vinylformamide crosslinking moiety; and polymers resulting from polymerization of at least one hybrid reactive N-vinylformamide monomer moiety having one N-vinylformamide functionality and at least one other reactive non-vinyl functionality and a hybrid N-vinylformamide crosslinking moiety having at least one N-vinylformamide functionality and at least one other reactive vinyl functionality. The invention further provides a wide variety of compositions comprising the novel crosslinked polymers.
    本发明提供了由至少一种反应性乙烯单体基团和多功能N-乙烯基甲酰胺交联基团聚合而成的聚合物;由至少一种反应性乙烯单体基团和具有至少一种N-乙烯基甲酰胺功能性和至少一种其他反应性乙烯功能性的混合N-乙烯基甲酰胺交联基团聚合而成的聚合物;由至少一种具有一种N-乙烯基甲酰胺功能性和至少一种其他反应性非乙烯功能性的混合反应性N-乙烯基甲酰胺单体基团和多功能N-乙烯基甲酰胺交联基团聚合而成的聚合物;以及由至少一种具有一种N-乙烯基甲酰胺功能性和至少一种其他反应性非乙烯功能性的混合反应性N-乙烯基甲酰胺单体基团和具有至少一种N-乙烯基甲酰胺功能性和至少一种其他反应性乙烯功能性的混合N-乙烃基甲酰胺交联基团聚合而成的聚合物。该发明还提供了包含新型交联聚合物的各种组合物。
  • TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
    申请人:Arvinas, Inc.
    公开号:US20180125821A1
    公开(公告)日:2018-05-10
    The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    本公开涉及双功能化合物,其作为tau蛋白的调节剂具有实用性。具体而言,本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体,另一端结合到tau蛋白的双功能化合物,使得tau蛋白与泛素连接酶靠近,以实现tau蛋白的降解(和抑制)。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
  • MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
    申请人:Arvinas, Inc.
    公开号:US20170008904A1
    公开(公告)日:2017-01-12
    The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    描述涉及MDM2结合化合物,包括包含相同结构的双功能化合物,这些化合物可作为靶向泛素化的调节剂,特别是根据本发明抑制各种多肽和其他蛋白质的化合物。具体而言,描述提供了一种化合物,其一端含有结合到MDM2 E3泛素连接酶的配体,另一端含有结合到靶蛋白的基团,使得靶蛋白与泛素连接酶靠近,以促使该蛋白的降解(和抑制)。可以合成出一系列具有广泛药理活性的化合物,与几乎任何类型的靶向多肽的降解/抑制一致。
  • LOW VISCOSITY LOW VOLATILITY LUBRICATING OIL BASE STOCKS AND METHODS OF USE THEREOF
    申请人:ExxonMobil Research and Engineering Company
    公开号:US20170183595A1
    公开(公告)日:2017-06-29
    A lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. The lubricating oil base stock has a high temperature high shear (HTHS) viscosity of less than about 1.7 cP as determined by ASTM D4683, and a Noack volatility from about 15 to about 90 percent as determined by ASTM D5800. A lubricating oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein. A method for improving one or more of thermal and oxidative stability, solubility and dispersancy of polar additives, deposit control and traction control in a lubricating oil by using as the lubricating oil a formulated oil containing the lubricating oil base stock including one or more monoesters represented by the formula (I), (II), (III) and (IV) as defined herein.
    一种润滑油基础油,包括根据本文所定义的公式(I)、(II)、(III)和(IV)表示的一个或多个单酯。该润滑油基础油的高温高剪切(HTHS)粘度小于约1.7厘泊,由ASTM D4683确定,挥发性从约15%到约90%,由ASTM D5800确定。一种含有根据本文所定义的公式(I)、(II)、(III)和(IV)表示的一个或多个单酯的润滑油基础油的润滑油。一种通过使用包含根据本文所定义的公式(I)、(II)、(III)和(IV)表示的一个或多个单酯的润滑油基础油的配制油来改善润滑油中的热稳定性、氧化稳定性、溶解性和分散性、沉积控制和牵引控制的方法。
  • [EN] DERIVATIVES OF BISACYLPHOSPHINIC ACID, THEIR PREPARATION AND USE AS PHOTOINITIATORS<br/>[FR] DÉRIVÉS D'ACIDE BISACYLPHOSPHINIQUE, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QUE PHOTO-INITIATEURS
    申请人:BASF SE
    公开号:WO2014095724A1
    公开(公告)日:2014-06-26
    Bisacylphosphine oxide or bisacylphosphine sulfide compounds of formula (I) or (II) wherein R1, R2, R3, R1a, R2a and R3a independently of each other are C1-C4alkyl, C1-C4alkoxy or halogen; X is O, NR5 or S; or, if R4 is CI, F or Br, X is a direct bond; Y is O or S; n is 1 or 2; R4, if n is 1, for example is hydrogen, (CO)R6, (CO)OR6, (CO)NR5R6, (SO2)-R6, C1-C28alkyl, R4, if n = 2, is for example C1-C18alkylene; R5 is for example hydrogen, or C1-C12alkyl; R6 is for example C1-C12alkyl; R7, R8 and R9 independently of each other for example are C1-C4alkyl; R10 is for example C2-C18alkylene; X1 is O or S; m is 1, 2 or 3; Q represents one or two inorganic or organic cations with a charge of m+; are suitable photoinitiators, available by a claimed process.
    双酰基膦氧化物或双酰基膦硫化物化合物的结构式(I)或(II),其中R1、R2、R3、R1a、R2a和R3a彼此独立地是C1-C4烷基、C1-C4烷氧基或卤素;X为O、NR5或S;或者,如果R4是CI、F或Br,则X为直接键;Y为O或S;n为1或2;例如,如果n为1,则R4为氢、(CO)R6、(CO)OR6、(CO)NR5R6、(SO2)-R6、C1-C28烷基;如果n=2,则R4为例如C1-C18烷基;例如,R5为氢或C1-C12烷基;例如,R6为C1-C12烷基;例如,R7、R8和R9彼此独立地为C1-C4烷基;例如,R10为C2-C18烷基;X1为O或S;m为1、2或3;Q代表带有m+电荷的一个或两个无机或有机阳离子,是通过声明的过程得到的合适的光引发剂
查看更多